» Articles » PMID: 23432647

Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: a Tale of a Variant Histone 3 Tail

Overview
Journal Brain Pathol
Date 2013 Feb 26
PMID 23432647
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Primary brain tumors occur in 8 out of 100 000 people and are the leading cause of cancer-related death in children. Among brain tumors, high-grade astrocytomas (HGAs) including glioblastoma multiforme (GBM) are aggressive and are lethal human cancers. Despite decades of concerted therapeutic efforts, HGAs remain essentially incurable in adults and children. Recent discoveries have revolutionized our understanding of these tumors in children and young adults. Recurrent somatic driver mutations in the tail of histone 3 variant 3 (H3.3), leading to amino acid substitutions at key residues, namely lysine (K) 27 (K27M) and glycine 34 (G34R/G34V), were identified as a new molecular mechanism in pediatric GBM. These mutations represent the pediatric counterpart of the recurrent mutations in isocitrate dehydrogenases (IDH) identified in young adult gliomas and provide a much-needed new pathway that can be targeted for therapeutic development. This review will provide an overview of the potential role of these mutations in altering chromatin structure and affecting specific molecular pathways ultimately leading to gliomagenesis. The distinct changes in chromatin structure and the specific downstream events induced by each mutation need characterizing independently if progress is to be made in tackling this devastating cancer.

Citing Articles

Imaging features and consideration of progression pattern of diffuse hemispheric gliomas, H3 G34-mutant.

Kibe Y, Chalise L, Ohka F, Motomura K, Nakahara N, Aoki K Acta Neuropathol Commun. 2025; 13(1):43.

PMID: 40016857 PMC: 11866785. DOI: 10.1186/s40478-025-01945-w.


Multimodal magnetic resonance imaging (MRI) of juvenile and adult diffuse hemispheric gliomas with H3 G34-mutation: a case description.

Hu W, Shao H, Yang X, Zheng L, Li S, Tan Q Quant Imaging Med Surg. 2024; 14(10):7740-7748.

PMID: 39429581 PMC: 11485332. DOI: 10.21037/qims-24-485.


Unravelling the mosaic: Epigenetic diversity in glioblastoma.

Lucchini S, Constantinou M, Marino S Mol Oncol. 2024; 18(12):2871-2889.

PMID: 39148319 PMC: 11619803. DOI: 10.1002/1878-0261.13706.


Epigenetics to clinicopathological features: a bibliometric analysis of H3 G34-mutant diffuse hemispheric glioma literature.

Roach J, Riviere-Cazaux C, Wells B, Boop F, Daniels D Childs Nerv Syst. 2024; 40(7):2009-2017.

PMID: 38613587 PMC: 11771222. DOI: 10.1007/s00381-024-06395-8.


Challenges and limitations of clinical trials in the adolescent and young adult CNS cancer population: A systematic review.

Byrne E, Pascoe M, Cooper D, Armstrong T, Gilbert M Neurooncol Adv. 2024; 6(1):vdad159.

PMID: 38250563 PMC: 10798804. DOI: 10.1093/noajnl/vdad159.


References
1.
Jones D, Kocialkowski S, Liu L, Pearson D, Backlund L, Ichimura K . Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008; 68(21):8673-7. PMC: 2577184. DOI: 10.1158/0008-5472.CAN-08-2097. View

2.
Kridel R, Sehn L, Gascoyne R . Pathogenesis of follicular lymphoma. J Clin Invest. 2012; 122(10):3424-31. PMC: 3461914. DOI: 10.1172/JCI63186. View

3.
Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A . Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010; 28(8):1337-44. DOI: 10.1200/JCO.2009.25.5463. View

4.
Downing J, Wilson R, Zhang J, Mardis E, Pui C, Ding L . The Pediatric Cancer Genome Project. Nat Genet. 2012; 44(6):619-22. PMC: 3619412. DOI: 10.1038/ng.2287. View

5.
Qu H, Jacob K, Fatet S, Ge B, Barnett D, Delattre O . Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol. 2010; 12(2):153-63. PMC: 2940568. DOI: 10.1093/neuonc/nop001. View